15 December 2014 in Proceedings of the National Academy of Sciences
Significance: The blood protein von Willebrand factor (VWF) is required for platelets to stop bleeding at sites of injury, and the metalloprotease ADAMTS13 limits platelet adhesion by cleaving VWF only when flowing blood stretches it, especially within a growing thrombus. This feedback inhibition is essential because ADAMTS13 deficiency causes fatal microvascular thrombosis. How ADAMTS13 recognizes VWF so specifically is not understood. We now find that ADAMTS13 is folded roughly in half so that its distal domains inhibit the metalloprotease domain. VWF relieves this autoinhibition and promotes its own destruction by allosterically activating ADAMTS13. Thus, VWF is both a substrate and a cofactor in this critical regulatory process.
22 September 2015 in Journal of Thrombosis and Haemostasis
Background Recently, conformational activation of ADAMTS‐13 was identified. This mechanism showed the evolution from a condensed conformation, in which the proximal MDTCS and distal T2‐CUB2 domains are in close contact with each other, to an activated, open structure due to binding with von Willebrand factor (VWF). Objectives Identification of cryptic epitope/exosite exposure after conformational activation and of sites of flexibility in ADAMTS‐13. Methods The activating effect of 25 anti‐T2‐CUB2 antibodies was studied in the FRETS‐VWF73 and the vortex assay. Cryptic epitope/exosite exposure was determined with ELISA and VWF binding assay. The molecular basis for flexibility was hypothesized through rapid automatic detection and alignment of repeats (RADAR) analysis, tested with ELISA using deletion variants and visualized using electron microscopy. Results Eleven activating anti‐ADAMTS‐13 antibodies, directed against the T5‐CUB2 domains, were identified in the FRETS‐VWF73 assay. RADAR analysis identified three linker regions in the distal domains. Interestingly, identification of an antibody recognizing a cryptic epitope in the metalloprotease domain confirmed the contribution of these linker regions to conformational activation of the enzyme. The proof of flexibility around both the T2 and metalloprotease domains, as shown by by electron microscopy, further supported this contribution. In addition, cryptic epitope exposure was identified in the distal domains, because activating anti‐T2‐CUB2 antibodies increased the binding to folded VWF up to ~3‐fold. Conclusion Conformational activation of ADAMTS‐13 leads to cryptic epitope/exosite exposure in both proximal and distal domains, subsequently inducing increased activity. Furthermore, three linker regions in the distal domains are responsible for flexibility and enable the interaction between the proximal and the T8‐CUB2 domains.
14 June 2013 in Journal of Thrombosis and Haemostasis
Background Most ADAMTS13 assays use non‐physiological conditions (low ionic strength, low pH, barium chloride), are subject to interference from plasma proteins, hemoglobin and bilirubin, and have limited sensitivity, especially for inhibitors. Objectives We addressed these constraints by designing a substrate that can be used in undiluted plasma. Methods A polypeptide was expressed in E. coli that corresponds to von Willebrand factor Gln1599‐Arg1668, with mutations N1610C and K1617R and an N‐terminal Gly. Substrate FRETS‐rVWF71 was prepared by modifying Cys1610 with DyLight 633 (abs 638 nm, em 658 nm) and the N‐terminus with IRDye QC‐1 (abs 500–800 nm). Assays were performed at pH 7.4 in 150 mm NaCl, 10 mm CaCl2. Results Serum and plasma anticoagulated with citrate or heparin had equivalent ADAMTS13 activity with FRETS‐rVWF71. Neither bilirubin (≤ 20 mg dL−1) nor hemoglobin (≤ 20 g L−1) interfered with product detection. Assays with FRETS‐rVWF71 and FRETS‐VWF73 gave similar results (R2 = 0.95) for plasma from 80 subjects with thrombotic microangiopathy, 22 subjects with other causes of thrombocytopenia, and 20 healthy controls. The limit of detection with FRETS‐rVWF71 for ADAMTS13 activity was ≤ 0.3%. Inhibitor assays with FRETS‐rVWF71 gave titers ~2.5‐fold higher than with FRETS‐VWF73 and clearly distinguished patients with and without inhibitors. Conclusions FRETS‐rVWF71 is suitable for ADAMTS13 assays in minimally diluted plasma or serum without interference from proteins, bilirubin or free hemoglobin in plasma. Optimized detection of ADAMTS13 inhibitors will facilitate the monitoring of antibody responses during the treatment of thrombotic thrombocytopenic purpura.
10 September 2021 in Blood Advances
Trauma-induced organ failure is characterized by endothelial dysfunction. The aim of this study was to investigate the role of von Willebrand factor (VWF) and its cleaving enzyme, ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motifs, member 13) in the occurrence of endothelial permeability and organ failure in trauma. In an observational study in a level-1 trauma center, 169 adult trauma patients with clinical signs of shock and/or severe injuries were included. Trauma was associated with low ADAMTS13 and high VWF antigen levels, thus generating an imbalance of ADAMTS13 to VWF. Patients who developed organ failure (23%) had greater ADAMTS13-to-VWF imbalances, persistently lower platelet counts, and elevated levels of high-molecular-weight VWF multimers compared with those without organ failure, suggesting microthrombi formation. To investigate the effect of replenishing low ADAMTS13 levels on endothelial permeability and organ failure using either recombinant human ADAMTS13 (rhADAMTS13) or plasma transfusion, a rat model of trauma-induced shock and transfusion was used. Rats in traumatic hemorrhagic shock were randomized to receive crystalloids, crystalloids supplemented with rhADAMTS13, or plasma transfusion. A 70-kDa fluorescein isothiocyanate–labeled dextran was injected to determine endothelial leakage. Additionally, organs were histologically assessed. Both plasma transfusion and rhADAMTS13 were associated with a reduction in pulmonary endothelial permeability and organ injury when compared with resuscitation with crystalloids, but only rhADAMTS13 resulted in significant improvement of a trauma-induced decline in ADAMTS13 levels. We conclude that rhADAMTS13 and plasma transfusion can reduce organ failure following trauma. These findings implicate the ADAMTS13-VWF axis in the pathogenesis of organ failure.